The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)

Status: Closed to Accrual


The purpose of this study is to evaluate the safety and efficacy of long-term dosing with ALN-TTR02 (patisiran) in patients with transthyretin (TTR) mediated amyloidosis (ATTR).

Eligibility Criteria

Inclusion Criteria

  • Have completed a patisiran study (i.e., completed the last efficacy visit in the parent study) and, in the opinion of the investigator, tolerated study drug
  • Be willing and able to comply with the protocol-required visit schedule and visit requirements and provide written informed consent

Exclusion Criteria

  • Any new or uncontrolled condition that could make the patient unsuitable for participation

Locations & Contacts


Mayo Clinic
Status: Active
Name Not Available

Trial Phase & Type

Trial Phase

Phase III

Trial Type


Lead Organization

Lead Organization
Alnylam Pharmaceuticals

Trial IDs

Primary ID ALN-TTR02-006
Secondary IDs NCI-2017-00574 ID NCT02510261